An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Recruiting

Phase 3

Dato-DXd & RilvegostomigAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Sponsor:

AstraZeneca

Code:

NCT07720284

Conditions

High-risk Muscle Invasive Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dato-DXd

Rilvegostomig

Durvalumab

Nivolumab

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-03. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-07-22.